An Interview from the 2016 EHA with Dr. Jeffrey Jones on the Role of Venetoclax in CLL By Brian Koffman, MD and Jeffrey Jones, MD, MPH In the first half of our video interview from the 2016... September 20, 20172016 ConferencesBy clladm1n
ASH 2016: Dr. Mark Wildgust on the Efficacy of Ibrutinib in Chronic Lymphocytic Leukemia On the third day of ASH (American Society of Hematology) 2016 Conference in San Diego, I interviewed Mark Wildgust, PhD,... July 11, 20172016 ConferencesBy Todd Dennison
ASH 2016: Which Patients With Chronic Lymphocytic Leukemia Become Resistant to Ibrutinib In the third part of my interview from ASH 2016 in San Diego, Dr. Wiestner from the NIH discusses who... June 27, 20172016 ConferencesBy Todd Dennison
ASH 2016: An Interview with Dr. George Follows on Late Resistance to Ibrutinib in CLL At ASH 2016 Dr. George Follows of Cambridge, England discusses our evolving understanding of life after ibrutinib for those of... June 27, 20172016 Conferences, Conference CoverageBy Brian Koffman
ASH 2016: Dr. Wiestner on Ibrutinib Failure with Either Progressive Chronic Lymphocytic Leukemia or Richter’s Transformation In my interview from ASH 2016 in San Diego, Dr. Adrian Wiestner of the National Institutes of Health talks about... June 20, 20172016 ConferencesBy Todd Dennison
ASH 2016: Dr.Kay on monoclonal B cell lymphocytosis, a precursor to CLL While we were at ASH 2016, Dr. Neil Kay and I discussed what we know about precursors to chronic lymphocytic... June 13, 20172016 ConferencesBy Todd Dennison
ASH 2016: Professor John Seymour on Using Venetoclax in Combination to Treat CLL Dr. Seymour from the Peter MacCallum Cancer Centre in Melbourne, Australia was one of the pioneers in the development of... June 6, 20172016 ConferencesBy Todd Dennison
ASH 2016: Dr. Anthony Mato on Sequencing Therapies in CLL (chronic lymphocytic leukemia) Managing chronic lymphocytic leukemia (CLL) can be similar to a chess match, but one that is played for the ultimate... May 30, 20172016 ConferencesBy Todd Dennison
ASH 2016: Dr. Anthony Mato Presents Real-World Data on Ibrutinib in CLL Dr. Anthony Mato of the University of Pennsylvania has been a pioneer in gathering real world data on chronic lymphocytic... May 24, 20172016 ConferencesBy Todd Dennison
ASH 2016: An Interview with Dr. John Pagel on Maintenance Therapy in CLL By Brian Koffman, MD and John Pagel, MD, PhD At ASH 2016 in San Diego, much of the chronic lymphocytic... April 5, 20172016 ConferencesBy clladm1n
